Jan 13 (Reuters) - Fractyl Health Inc GUTS.O:
FRACTYL HEALTH ANNOUNCES POSITIVE INITIAL CLINICAL RESULTS DEMONSTRATING WEIGHT MAINTENANCE FOLLOWING GLP-1 DISCONTINUATION AND REVITA PROCEDURE IN FIRST PATIENT OF THE REVEAL-1 COHORT
FIRST STUDY PATIENT ACHIEVES 15% WEIGHT LOSS WITH TIRZEPATIDE OVER A PERIOD OF 7 MONTHS
Source text: ID:nGNXRy0fc
Further company coverage: GUTS.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.